Catalyst Pharmaceuticals, Inc. (CPRX) News
Catalyst Pharmaceuticals, Inc. (CPRX)
Today's Latest Price: $3.48 USD
Updated Nov 24 4:00pm
Add CPRX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter CPRX News Items
CPRX News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CPRX News From Around the Web
Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.
Catalyst to appeal ruling in favor of FDA decision on Firdapse's competitor drugCatalyst Pharmaceuticals slides ([[CPRX]] -7.8%) after a federal judge upheld a previous rule from a Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus and dismissed the company’s lawsuit against the FDA regarding the approval of a rival drug, Ruzurgi for the treatment of Lambert-Eaton Myasthenic Syndrome ((LEMS)) from Jacobus... |
ROCE Insights For Catalyst PharmaceuticalsCatalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 … |
Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update- Firdapse® Second Quarter Net Revenues of $29.6 Million - Health Canada Approves Marketing Authorization for Firdapse® for Treating LEMS Patients -… |
Earnings Preview: Catalyst PharmaceuticalsCatalyst Pharmaceuticals (NASDAQ: CPRX) announces its next round of earnings this Monday, August 10. Here is Benzinga's everything-that-matters … |
Here's How Much Investing $1,000 In Catalyst Pharmaceuticals In 2010 Would Be Worth TodayInvestors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Catalyst’s Solid Decade: One stock that kept pace over the last decade was biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in the past decade came in 2018 when the company’s Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan … Full story available on Benzinga.com |
Catalyst Pharma down 13% on adverse ruling in FDA lawsuitCatalyst Pharmaceuticals ([[CPRX]] -12.7%) is under pressure on 77% higher volume in reaction to an adverse development in its lawsuit against the FDA related to Firdapse (amifampridine phosphate), approved in the U.S. in November 2018 for adults with an autoimmune disorder called Lambert-Eaton syndrome ((LEMS)), an Orphan Drug-tagged indication which is... |
Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDACORAL GABLES, Fla., July 31, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the Magistrate Judge considering Catalyst's lawsuit against the FDA has filed a Report and Recommendation in which she recommends to the District Judge handling the case that she grant the FDA's and Jacobus' motions for summary judgement and deny Catalyst's motion for summary judgement. Catalyst is currently reviewing the Magistrate Judge's decision, which it believes to be incorrect as a matter of law, and intends to pursue the case further with the District Judge. The decision on whether to grant or deny Catalyst's motion for summary judgement remains with the District Judge handling the case. Patrick J. McEnany, the Company's... |
Catalyst Pharma files for $200M mixed shelfCatalyst Pharmaceuticals (CPRX) has filed a preliminary prospectus for a $200M mixed shelf offering.... |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Catalyst Pharmaceuticals, Inc. - CPRXNew York, New York--(Newsfile Corp. - July 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/catalyst-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, ... |
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Catalyst Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty ClaimsNEW YORK, NY / ACCESSWIRE / July 14, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Catalyst Pharmaceuticals, Inc. (NASDAQ: ... |
